In recent years, some evidence suggested that IGF-1/IGF-1R polymorphisms are potential predictive/prognostic markers for cetuximab efficacy in metastatic CRC patients presenting wild- type KRAS[54]. The gene discussed is KRAS; the disease is colorectal carcinoma.